Late-onset hemorrhagic cystitis (HC) after allogeneic hematopoietic stem cell transplantation (HSCT) has been associated with BK virus (BKV). Antiviral drugs are of limited efficacy and the optimal ...
Hemorrhagic cystitis (HC) is a frequent and sometimes life-threatening complication after hematopoietic SCT (HSCT). Many therapeutic approaches have been performed to control HC, but their effect is ...
PITTSBURGH--(BUSINESS WIRE)--Lipella Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on improving cancer survivorship, today announced it has begun recruiting patients in the ...
Please provide your email address to receive an email when new articles are posted on . BK virus-specific cytotoxic T lymphocytes from healthy donors appeared safe and effective for patients with BK ...
Please provide your email address to receive an email when new articles are posted on . The FDA granted orphan drug designation to posoleucel for the treatment of virus-associated hemorrhagic cystitis ...
Phase 3 registrational study of posoleucel in virus-associated hemorrhagic cystitis is ongoing An inflammatory disease of the bladder, virus-associated HC is a serious complication of hematopoietic ...
I encountered my most memorable patient while working as a urology nurse practitioner at a large urban hospital. The patient was 70 years old, alert and oriented and lived in a nursing home. He had a ...
BK virus-associated hemorrhagic cystitis (BKV-HC) is a common complication of allogenic hematopoietic stem cell transplantation (AHSCT), particularly in recipients of alternative donor transplants, ...
(RTTNews) - Biotechnology company Lipella Pharmaceuticals Inc. (LIPO) announced top line results for its recently completed Phase 2a clinical trial evaluating the safety and efficacy of its drug ...
Dublin, March 27, 2026 (GLOBE NEWSWIRE)-- The "Pelvic Cancer Induced Hemorrhagic Cystitis Market Report 2026" has been added to ResearchAndMarkets.com's offering. The pelvic cancer induced hemorrhagic ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug ...